BACKGROUND: KRAS mutated colorectal cancers (CRC) are reported to be associated with a poor response to anti-EGFR monoclonal antibody therapy and poor prognosis. We studied the rates of KRAS mutated tumors in patients with peritoneal carcinomatosis from CRC and investigated the association of KRAS status with specific clinicopathologic factors. METHODS: A retrospective observational study of tumor specimens from 23 patients with peritoneal carcinomatosis from CRC was performed using standard genomic DNA sampling techniques to identify KRAS mutations. Correlation between clinicopathologic factors and KRAS mutation status was performed using the Fisher exact test or χ test, as appropriate. RESULTS: Eleven (48%) of 23 patients had KRAS mutations. There were no statistically significant correlations in patient demographics, tumor pathology, surgical evaluation, treatments, or survival outcomes for peritoneal carcinomatosis between patients with KRAS mutations or wild-type KRAS status. CONCLUSION: The prevalence of KRAS mutation in CRC patients with peritoneal carcinomatosis is 48% in this preliminary study and clinicopathologic factors appear to be independent of mutation status.
BACKGROUND:KRAS mutated colorectal cancers (CRC) are reported to be associated with a poor response to anti-EGFR monoclonal antibody therapy and poor prognosis. We studied the rates of KRAS mutated tumors in patients with peritoneal carcinomatosis from CRC and investigated the association of KRAS status with specific clinicopathologic factors. METHODS: A retrospective observational study of tumor specimens from 23 patients with peritoneal carcinomatosis from CRC was performed using standard genomic DNA sampling techniques to identify KRAS mutations. Correlation between clinicopathologic factors and KRAS mutation status was performed using the Fisher exact test or χ test, as appropriate. RESULTS: Eleven (48%) of 23 patients had KRAS mutations. There were no statistically significant correlations in patient demographics, tumor pathology, surgical evaluation, treatments, or survival outcomes for peritoneal carcinomatosis between patients with KRAS mutations or wild-type KRAS status. CONCLUSION: The prevalence of KRAS mutation in CRC patients with peritoneal carcinomatosis is 48% in this preliminary study and clinicopathologic factors appear to be independent of mutation status.
Authors: Marco Tonello; Dario Baratti; Paolo Sammartino; Andrea Di Giorgio; Manuela Robella; Cinzia Sassaroli; Massimo Framarini; Mario Valle; Antonio Macrì; Luigina Graziosi; Federico Coccolini; Piero Vincenzo Lippolis; Roberta Gelmini; Marcello Deraco; Daniele Biacchi; Francesco Santullo; Marco Vaira; Katia Di Lauro; Fabrizio D'Acapito; Fabio Carboni; Giuseppe Giuffrè; Annibale Donini; Paola Fugazzola; Pinuccia Faviana; Lorena Sorrentino; Antonio Scapinello; Paola Del Bianco; Antonio Sommariva Journal: Ann Surg Oncol Date: 2021-11-16 Impact factor: 5.344
Authors: Manuel Díez-Alonso; Fernando Mendoza-Moreno; Remedios Gómez-Sanz; Belén Matías-García; Enrique Ovejero-Merino; Raquel Molina; Sonia Soto-Schütte; Alberto San Juan; Alberto Gutierrez-Calvo Journal: Int J Surg Oncol Date: 2021-09-13
Authors: Jurriaan B Tuynman; Louis Vermeulen; Kristiaan J Lenos; Sander Bach; Leandro Ferreira Moreno; Sanne Ten Hoorn; Nina R Sluiter; Sanne Bootsma; Felipe A Vieira Braga; Lisanne E Nijman; Tom van den Bosch; Daniel M Miedema; Erik van Dijk; Bauke Ylstra; Ruth Kulicke; Fred P Davis; Nicolas Stransky; Gromoslaw A Smolen; Robert R J Coebergh van den Braak; Jan N M IJzermans; John W M Martens; Sally Hallam; Andrew D Beggs; Geert J P L Kops; Nico Lansu; Vivian P Bastiaenen; Charlotte E L Klaver; Maria C Lecca; Khalid El Makrini; Clara C Elbers; Mark P G Dings; Carel J M van Noesel; Onno Kranenburg; Jan Paul Medema; Jan Koster; Lianne Koens; Cornelis J A Punt; Pieter J Tanis; Ignace H de Hingh; Maarten F Bijlsma Journal: Nat Commun Date: 2022-08-04 Impact factor: 17.694